Document Detail


Improved growth factor directed vascularization into fibrin constructs through inclusion of additional extracellular molecules.
MedLine Citation:
PMID:  17223139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Using the chick chorioallantoic membrane assay (CAM) and a novel histological technique, we investigated the ability of blood vessels to directly invade fibrin-based scaffolds. In our initial experiments utilizing vascular endothelial growth factor (VEGF(165)), we found no direct invasion. Instead, the fibrin was completely degraded and replaced with highly vascularized new tissue. Addition of fibroblast growth factor-2 (FGF-2), bone morphogenic protein-2 (BMP-2), or platelet-derived growth factor-BB (PDGF-BB) to the fibrin construct also did not result in construct vascularization. Because natural and regenerating tissues exhibit complex extracellular matrices (ECMs), we hypothesized that a more complex scaffold may improve blood vessel invasion. Addition of fibronectin, hyaluronic acid, and collagen type I within 20 mg/mL fibrin constructs resulted in no significant improvement. However, the same additive concentrations within 10 mg/mL fibrin constructs resulted in dramatic improvements, specifically with hyaluronic acid. Overall, we believe that these results indicate the importance of structural and functional cues of not only in the initial scaffold but also as the construct is degraded and remodeled. Furthermore, the CAM assay may represent a useful model for understanding ECM interactions as well as for screening and designing tissue-engineered scaffolds.
Authors:
J D Smith; M E Melhem; K T Magge; A S Waggoner; P G Campbell
Related Documents :
2261279 - Accidental application of cyanoacrylate to the mouth.
11305429 - Adhesive tape analysis: establishing the evidential value of specific techniques.
22624859 - Cannabidiol inhibits angiogenesis by multiple mechanisms.
24040589 - Transection of gut loop due to post-operative adhesions.
22877639 - Direct thrombin inhibitor-bivalirudin functionalized plasma polymerized allylamine coat...
1874669 - Effect of tissue adhesives and suture patterns on experimentally induced teat laceratio...
17487559 - Carcinoembryonic antigen-stimulated thp-1 macrophages activate endothelial cells and in...
24622969 - Intracellular stresses in patterned cell assemblies.
9724279 - Depression of endothelial and smooth muscle cell oxygen consumption by endotoxin.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2007-01-16
Journal Detail:
Title:  Microvascular research     Volume:  73     ISSN:  0026-2862     ISO Abbreviation:  Microvasc. Res.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-02-19     Completed Date:  2007-04-24     Revised Date:  2014-09-15    
Medline Journal Info:
Nlm Unique ID:  0165035     Medline TA:  Microvasc Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  84-94     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Allantois / blood supply
Animals
Bone Morphogenetic Protein 2
Bone Morphogenetic Proteins / pharmacology
Chick Embryo
Chorion / blood supply
Collagen Type I / pharmacology
Extracellular Matrix Proteins / pharmacology*
Fibrin
Fibroblast Growth Factor 2 / pharmacology
Fibronectins / pharmacology
Gels
Growth Substances / pharmacology*
Humans
Hyaluronic Acid / pharmacology
Microscopy, Electron, Scanning
Neovascularization, Physiologic / drug effects*
Platelet-Derived Growth Factor / pharmacology
Proto-Oncogene Proteins c-sis
Recombinant Proteins / pharmacology
Transforming Growth Factor beta / pharmacology
Vascular Endothelial Growth Factor A / pharmacology
Grant Support
ID/Acronym/Agency:
1R01 EB 00364-01/EB/NIBIB NIH HHS; 1T32 EB 00424-03/EB/NIBIB NIH HHS; R01 EB004343/EB/NIBIB NIH HHS; R01 EB004343-03/EB/NIBIB NIH HHS
Chemical
Reg. No./Substance:
0/BMP2 protein, human; 0/Bone Morphogenetic Protein 2; 0/Bone Morphogenetic Proteins; 0/Collagen Type I; 0/Extracellular Matrix Proteins; 0/Fibronectins; 0/Gels; 0/Growth Substances; 0/Platelet-Derived Growth Factor; 0/Proto-Oncogene Proteins c-sis; 0/Recombinant Proteins; 0/Transforming Growth Factor beta; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/platelet-derived growth factor BB; 103107-01-3/Fibroblast Growth Factor 2; 9001-31-4/Fibrin; 9004-61-9/Hyaluronic Acid
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ecosystem objectives to support the UK vision for the marine environment.
Next Document:  Effects of ability- and chance-determined competition outcome on testosterone.